Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 44 peer-reviewed journal articles Updated
Dermatology

Multicentric reticulohistiocytosis: A Patient Guide

At a Glance

MRH is a rare immune-cell disorder that can cause skin nodules and rapidly destructive joint inflammation, especially in the hands. Prompt rheumatology treatment may help prevent irreversible damage, and individualized cancer screening may be recommended because MRH can be associated with cancer.

Multicentric Reticulohistiocytosis (MRH) is an exceptionally rare condition that sits at the intersection of dermatology and rheumatology. It occurs when specific immune cells, called histiocytes, behave abnormally and gather in the skin, the joints, and occasionally internal organs [1]. This process often manifests as firm, reddish-brown bumps—most famously appearing in a “coral bead” pattern around the fingernails—alongside significant joint pain and swelling [2][3]. Because fewer than 300 cases have been documented in the medical literature, receiving this diagnosis can feel like entering uncharted territory. Understanding the disease’s behavior is the first step toward protecting your long-term health.

The most critical aspect of MRH is its impact on the joints, which requires urgent rheumatology assessment [4][5]. Unlike many other forms of arthritis that develop slowly over decades, the inflammation in MRH can be a time-sensitive, potentially destructive joint disease. It often involves the small joints of the hands and can lead to permanent bone loss and joint collapse, a condition known as arthritis mutilans [4][6]. Because the damage caused by these erosions generally cannot be reversed, starting systemic treatment promptly is the most effective way to help preserve your mobility and independence [7][8].

Beyond the skin and joints, MRH is reported to be associated with other underlying health conditions, most notably malignancy [9]. Approximately one-quarter to one-third of reported patients with MRH may have an associated cancer, which can sometimes appear before, during, or even years after the skin and joint symptoms begin [10][11]. However, it is important to reassure yourself that an MRH diagnosis does not mean you definitely have cancer. Instead, it means that age-, anatomy-, personal-risk-, and family-history-appropriate population screening, plus clinician-directed evaluation, should be part of your individualized care plan [12][11].

While there is no treatment specifically approved for MRH due to its rarity, the treatment landscape has expanded based on case reports and small series [13]. Rheumatologists use off-label arthritis medications—including conventional drugs like methotrexate, biologic therapies, and newer targeted treatments called JAK inhibitors—to calm the immune system and attempt to halt the progression of the disease [3][13][14]. Although MRH has been reported to eventually enter a period of spontaneous remission in some cases, the goal of modern care is to prevent joint damage before that point. By working closely with a specialized care team, you can navigate the complexities of this rare condition with a focus on active preservation and long-term wellness [8][15].

In this guide

6 chapters

01

Building Your Foundation: Understanding MRH

Learn what multicentric reticulohistiocytosis (MRH) means for your skin and joints, why prompt care matters, and how cancer screening and treatment are planned.

02

Recognizing the Signs: Skin and Joint Symptoms

Learn to recognize multicentric reticulohistiocytosis symptoms, including coral-bead skin nodules, DIP joint arthritis, bone damage, and rare warning signs.

03

The Microscopic Map: Biology and Diagnosis

Learn how multicentric reticulohistiocytosis is diagnosed with biopsy findings, CD68, CD1a, and S100 markers, and distinguished from RA and dermatomyositis.

04

Looking Deeper: Malignancy and Autoimmune Risks

Learn about multicentric reticulohistiocytosis, its links to cancer and autoimmune disease, recommended screening, warning symptoms, and personalized follow-up

05

Preserving Function: Treatment Strategies

Learn how MRH treatment protects joint function, including steroids, DMARDs, biologics, JAK inhibitors, bisphosphonates, surgery, therapy, and medication safety.

06

The Long View: Survivorship and Monitoring

Learn how multicentric reticulohistiocytosis monitoring tracks cancer risk, joint damage, medication safety, infections, and lung symptoms during long-term care.

Common questions in this guide

What is multicentric reticulohistiocytosis, and what symptoms does it cause?
Multicentric reticulohistiocytosis, or MRH, is an exceptionally rare disorder in which certain immune cells collect in the skin, joints, and sometimes internal organs. It commonly causes firm reddish-brown skin bumps, including a coral-bead pattern around the fingernails, along with painful, swollen joints.
Why is early rheumatology care important for MRH?
MRH can inflame and erode joints, especially the small joints of the hands. Without prompt control, bone loss may cause joint collapse and arthritis mutilans, which can permanently limit movement and independence. Early assessment by a rheumatologist helps the care team start treatment aimed at protecting joint function.
Does having MRH mean that I have cancer?
Not necessarily. About one-quarter to one-third of reported people with MRH have an associated cancer, but many do not, and an MRH diagnosis alone does not prove that cancer is present. Your clinicians can choose screening and any additional evaluation based on your age, relevant anatomy, personal risk factors, and family history.
How is multicentric reticulohistiocytosis treated?
There is no treatment specifically approved for MRH because it is so rare. Rheumatologists may use off-label medicines such as methotrexate, biologic therapies, or JAK inhibitors to calm the immune system and slow joint damage. The best choice depends on your disease and overall health.
How can I tell whether MRH treatment is controlling joint damage?
New or worsening joint pain, swelling, stiffness, or loss of movement can signal that inflammation remains active. Trouble with daily activities, such as typing, cooking, or dressing, should also be reported, and your rheumatologist can assess whether bone erosions are progressing. Contact your care team promptly rather than waiting for permanent damage.
Which specialists should I see for MRH?
MRH is usually managed by a rheumatologist and dermatologist working together. Because the condition is rare, your team may also seek input from a specialist center or another clinician with experience in MRH. Rheumatology assessment is especially important because joint damage can progress quickly.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Multicentric reticulohistiocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How quickly can we start systemic treatment to help prevent irreversible damage to my finger joints?
  2. 2.Based on my age, personal risk factors, and family history, what specific cancer screenings should we pursue?
  3. 3.What are the signs that my current treatment might not be working fast enough to stop bone erosions?
  4. 4.Are there specific movements or activities I should avoid to protect my joints while the disease is active?
  5. 5.Given the rarity of my condition, is there a specialist center or a specific rheumatologist you consult with for MRH?

References

References (15)
  1. 1

    Reddish-brown, papulonodular skin lesions in the periungual region.

    Nosewicz J, Moad JC, Kaffenberger J

    Dermatology online journal 2023; (29(1)) doi:10.5070/D329160219.

    PMID: 37040916
  2. 2

    Multicentric Reticulohistiocytosis.

    Goldberg LA, Hsu S

    Skinmed 2024; (22(6)):452-453.

    PMID: 39748578
  3. 3

    Clinical characteristics of multicentric reticulohistiocytosis and distinguished features from rheumatoid arthritis: a single-center experience in China.

    Zou XJ, Qiao L, Li F, et al.

    Orphanet journal of rare diseases 2022; (17(1)):164 doi:10.1186/s13023-022-02311-y.

    PMID: 35413870
  4. 4

    Multicentric Reticulohistiocytosis: Elective Excision of Symptomatic Hand Nodules With 1-Year Follow-Up.

    Mead M, Baes T, Dass G

    The Journal of hand surgery 2020; (45(5)):457.e1-457.e5 doi:10.1016/j.jhsa.2019.06.001.

    PMID: 31320232
  5. 5

    Efficacy of Vinblastine and Prednisone in Multicentric Reticulohistiocytosis With Onset in Infancy.

    Jha VK, Kumar R, Kunwar A, et al.

    Pediatrics 2016; (137(6)).

    PMID: 27199388
  6. 6

    Bilateral Total Hip Arthroplasty in a Rare Case of Multicentric Reticulohistiocytosis.

    Saibaba B, Sen RK, Das A, Sharma A

    Clinics in orthopedic surgery 2015; (7(4)):509-14 doi:10.4055/cios.2015.7.4.509.

    PMID: 26640636
  7. 7

    The utility of FDG-PET/CT imaging in the evaluation of multicentric reticulohistiocytosis: A case report.

    Asano T, Suzutani K, Watanabe A, et al.

    Medicine 2018; (97(33)):e11449 doi:10.1097/MD.0000000000011449.

    PMID: 30113451
  8. 8

    Looks Can Be Deceiving: A Case Report on Multicentric Reticulohistiocytosis Successfully Treated with Rituximab.

    Lim K, D'Souza J, Vasquez JB, Vuyyuru S

    Cureus 2017; (9(5)):e1220 doi:10.7759/cureus.1220.

    PMID: 28589069
  9. 9

    Multicentric reticulohistiocytosis: the Mayo Clinic experience (1980-2017).

    Sanchez-Alvarez C, Sandhu AS, Crowson CS, et al.

    Rheumatology (Oxford, England) 2020; (59(8)):1898-1905 doi:10.1093/rheumatology/kez555.

    PMID: 31742640
  10. 10

    Multicentric reticulohistiocytosis revealing a ductal breast cancer in situ: A case report with dermoscopic and histopathological findings.

    Palma Peña S, Neely Erdos G, Buchroithner Haase C, Pinto Viguera C

    Medwave 2024; (24(5)):e2914 doi:10.5867/medwave.2024.05.2914.

    PMID: 38896878
  11. 11

    A Novel Case of Multicentric Reticulohistiocytosis Associated with Renal Cell Carcinoma Successfully Treated with Infliximab and Methotrexate.

    Patel S, Alhajj M, Brimhall C

    Case reports in dermatology 2023; (15(1)):10-16 doi:10.1159/000528254.

    PMID: 36632441
  12. 12

    Multicentric reticulohistiocytosis: A case report with response to adalimumab.

    Kim S, Khatchaturian EM, Dehesa L

    Clinical case reports 2020; (8(8)):1560-1563 doi:10.1002/ccr3.2926.

    PMID: 32884795
  13. 13

    Successful treatment of multicentric reticulohistiocytosis with JAK inhibitor: a case series.

    Hilliquin S, Dupin N, Franck N, et al.

    RMD open 2026; (12(2)) doi:10.1136/rmdopen-2025-006661.

    PMID: 42097694
  14. 14

    Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition.

    Pamfil C, Taki MA, Candrea E, et al.

    International journal of molecular sciences 2026; (27(6)) doi:10.3390/ijms27062898.

    PMID: 41898754
  15. 15

    Assessment and effective targeting of Interleukin-1 in multicentric reticulohistyocytosis.

    Aouba A, Leclerc-Mercier S, Fraitag S, et al.

    Joint bone spine 2015; (82(4)):280-3.

    PMID: 25776445

This page is for informational purposes only and does not constitute medical advice. A rheumatologist and dermatologist can help tailor joint-protective treatment and cancer screening to your situation.